Litcius/Paper detail

SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis

Hongyan Liu, Vikas S. Sridhar, Bruce A. Perkins, Julio Rosenstock, David Z.I. Cherney

2022Current Diabetes Reports11 citationsDOI

Topics & Concepts

MedicineDiabetic ketoacidosisDiabetes mellitusIntensive care medicineType 1 diabetesKidney diseaseType 2 diabetesClinical trialType 2 Diabetes MellitusInternal medicineEndocrinologyDiabetes Treatment and ManagementPancreatic function and diabetesDiabetes Management and Research
SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis | Litcius